Want to see HK:0455 full AI Analyst Report?
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.08 - HK$0.17
Previous CloseN/A
Volume4.00K
Average Volume (3M)147.67K
Market Cap
HK$260.16M
Enterprise ValueHK$284.88
Total Cash (Recent Filing)HK$64.81M
Total Debt (Recent Filing)HK$132.66M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.26%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume318,200
30 Day Avg. Volume147,666
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate debt-to-equity indicates the balance sheet is not heavily burdened by borrowings, preserving some financial flexibility. This gives Tianda more capacity to manage operating volatility and fund priorities without the immediate pressure associated with excessive leverage.
2025 Cash Flow ImprovementThe return to positive operating and free cash flow in 2025 is a constructive improvement in internal funding ability. If sustained, stronger cash conversion could reduce reliance on external financing and support ongoing operations despite the company’s profitability challenges.
Healthy Gross Margin BaseA gross margin of about 41% still provides a meaningful contribution after product costs, suggesting the business retains some underlying product economics. Preserving that margin base could support recovery if revenue stabilizes and operating expenses become better aligned with sales.
Bears Say
Persistent Losses And Margin DeteriorationPersistent net and operating losses indicate that the current business model is not converting gross profit into sustainable earnings. The sharp margin deterioration reduces financial resilience, limits internally generated capital, and makes a durable recovery dependent on meaningful operating improvement.
Declining RevenueA shrinking revenue base limits the company’s ability to absorb fixed operating costs and achieve scale benefits. Continued sales contraction would make it harder to restore profitability, sustain investment, and generate the operating leverage needed to reverse the current earnings weakness.
Volatile Cash Generation And Equity ErosionThe combination of uneven cash generation and declining shareholder equity points to ongoing funding and value-retention risk. Even with positive cash flow in 2025, prior deficits and cumulative losses could constrain investment capacity and weaken the balance sheet if performance does not stabilize.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.08 and its highest was HK$0.17 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$260.16M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
Tianda Pharmaceuticals Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 185 days.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Aug 10, 2026. The company reported -HK$0.015 earnings per share for the quarter.
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. pays a Notavailable dividend of HK$0.003 which represents an annual dividend yield of 2.26%. See more information on Tianda Pharmaceuticals Ltd. dividends here
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.015 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 2012, focuses on the research, development, manufacturing, and distribution of a wide array of pharmaceutical, biotechnology, and healthcare products. Its commercial reach extends across Mainland China, Hong Kong, and Australia. The company's diverse portfolio includes traditional Chinese medicines, chemical drugs, biological products, and medical appliances. These offerings target numerous therapeutic areas, such as cardio-cerebrovascular health, pediatric care, anti-flu and respiratory conditions, anti-infection, detoxification, and urological disorders. Health supplements are specifically marketed under the "Herb Valley" and "Tuokang" brand names. Furthermore, Tianda Pharmaceuticals is involved in the wholesale and retail of Chinese herbal medicines, traditional Chinese medicine (TCM) decoction pieces, and other Chinese medicinal products, provides Chinese medical services, and trades agricultural by-products.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―